Pregnancy Clinical Trial
Official title:
A Randomized Double-blinded Trial of the Effects of Bupivacaine Induced Motor Blockade on the Second Stage of Labor
The aim of this study is to measure the effects of bupivacaine administered via epidural
catheters on indices of motor blockade ascertained during the second stage of labor. This is
a randomized, double-blind, controlled trial designed to address the primary research
question: Does bupivacaine lengthen the second stage of labor? The secondary research
question is: Is there other evidence of motor blockade attributable to bupivacaine during the
second stage of labor?
The investigators know from prior studies that the length of the second stage in nulliparous
women delivered at Parkland Hospital without epidural analgesia is 28 minutes. The
investigators hypothesize in this now proposed study that epidural analgesia with bupivacaine
will significantly increase this baseline from 28 minutes to 37 minutes or more (a 33%
increase) thus implicating motor blockade. Baseline data for the Bromage and Breen scores
during the second stage as well as the uterine contractility data are not available as these
indices of motor blockade have not here-to-fore been studied in this context.
Currently at Parkland Hospital, 82% of nulliparous women undergoing induction of labor at
term receive continuous epidural infusions with bupivacaine during the first and second
stages of labor. Such women will be identified when admitted for scheduled inductions at
Parkland. After informed consent is obtained standard management of labor induction will be
provided. Those consented women reaching 8 cm cervical dilation will be randomized. Group I
will receive bupivacaine plus fentanyl via epidural catheter during the second stage (i.e. 10
cm dilation) and Group II will receive only fentanyl infusion via epidural catheter (see
study procedure below). Both the patient and the caregiver will be blinded as to whether the
patient is in the bupivacaine plus fentanyl arm or the fentanyl only arm. To detect a 33%
increase (from 28 minutes to 37 minutes) in the primary outcome the investigators need a
total of 310 women enrolled in the study (or 155 per arm). Assuming a 30% consent rate and
given that approximately 1000 women meet the inclusion criteria each year at Parkland, the
investigators project that this study could be completed in 12 months.
Nulliparous women scheduled for labor inductions on Monday through Friday and who have
consented to this study will be randomized to one of two arms: bupivacaine plus fentanyl
epidural analgesia throughout labor and delivery (including the second stage) or epidural
bupivacaine plus fentanyl until 8 cm cervical dilation and only fentanyl thereafter. From
activation of epidural analgesia to 8 cm cervical dilation the prevailing standard epidural
technique in use at Parkland Hospital will be used. Briefly, 19-ga multi-orifice epidural
catheter is placed using 17-ga 3 ½cm Tuohy needle into the L3-L4 lumbar interspace. Lactated
Ringers solution, 500-1000mL will be infused during placement of the epidural catheter to
mitigate hypotension. A test dose using 1.5% lidocaine with 1:200,000 epinephrine, 3mL, will
be given via the epidural catheter. If the test dose is negative, then an initial bolus of
0.25% bupivacaine, 4-8mL, with fentanyl 100mcg is given via the catheter. After securing the
epidural catheter the patient will be placed in the supine position and the anesthetic
sensory level measured with the desired level of T6-T8. Once a T6-T8 sensory block is secured
the epidural infusion using 0.125% bupivacaine with 2mcg/mL fentanyl at 10mL/hr will be
started.
At any time during epidural infusion the epidural catheter may be replaced at the discretion
of the anesthesia provider for inadequate analgesia. Ephedrine or phenylephrine will be given
intravenously for maternal hypotension defined as systolic blood pressure ≤ 90 mmHg or a
decrease of 20% systolic blood pressure from patient's baseline.
Randomization will occur when the woman reaches 8 cm cervical dilation. Envelopes containing
cassettes will be sequentially randomized by Dr. McIntire and given to the attending
obstetrical anesthesiologist containing one of two medications. Group I will receive a 100mL
epidural cassette of 0.125% bupivacaine with fentanyl 2mcg/mL to be infused at 10mL/hr. Group
II will receive a 100mL cassette of fentanyl 10mcg/mL (to be infused at 10mL/hr. Both groups
will have the same rate of epidural infusion such that the patient, nurse, obstetrician, and
anesthesia providers will be blinded to the randomized treatment group. The Parkland
Investigational Drug Service (IDS) will provide the study drugs.
The patient may request a 5mL bolus from the epidural infusion every 30 minutes if pain
relief is inadequate. The obstetrician can also give patients in either study group 25mg of
intravenous meperidine every hour for up to two doses if pain relief is unsatisfactory. The
study regimen will continue until spontaneous delivery of the infant or until which time
operative vaginal delivery or cesarean delivery is planned. At this point the study will be
over and routine anesthesia care resumed.
The standard of care for management of labor induction at Parkland requires continuous
electronic fetal heart rate monitoring (EFM) as well as uterine contraction monitoring. The
standard is to apply EFM internal transducers when the membranes are ruptured. Standard fetal
monitors equipped with laptop computers will be used to electronically store the fetal heart
rate and uterine contraction data during this study. This will permit qualification of
uterine contractility during the second stage of labor. The Bromage and Breen scores for
motor blockade will be assessed at complete cervical dilation and at 30, 60, and 90 minutes
thereafter. The scoring system is as follows:
Score Criteria
1. Unable to move feet or knees (complete block)
2. Able to move feet only
3. Just able to move knees
4. Detectable weakness of hip flexion while supine
5. No weakness of hip flexion
6. Able to perform partial knee bend
Visual analog pain (VAS) scores for the adequacy of epidural analgesia from 1-10 will also be
assessed at each time point used for the Bromage and Breen scores.
Data collection will include maternal demographic characteristics as well as antepartum and
intrapartum obstetrical features. Condition of the infant at birth based on Apgar scores and
umbilical artery blood pH, as well as neonatal outcomes will be ascertained.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03442582 -
Afluria Pregnancy Registry
|
||
Terminated |
NCT02161861 -
Improvement of IVF Fertilization Rates, by the Cyclic Tripeptide FEE - Prospective Randomized Study
|
N/A | |
Not yet recruiting |
NCT05934318 -
L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE)
|
N/A | |
Enrolling by invitation |
NCT05415371 -
Persistent Poverty Counties Pregnant Women With Medicaid
|
N/A | |
Completed |
NCT04548102 -
Effects of Fetal Movement Counting on Maternal and Fetal Outcome Among High Risk Pregnant Woman
|
N/A | |
Completed |
NCT03218956 -
Protein Requirement During Lactation
|
N/A | |
Completed |
NCT02191605 -
Computer-delivered Screening & Brief Intervention for Marijuana Use in Pregnancy
|
N/A | |
Completed |
NCT02223637 -
Meningococcal Quadrivalent CRM-197 Conjugate Vaccine Pregnancy Registry
|
||
Recruiting |
NCT06049953 -
Maternal And Infant Antipsychotic Study
|
||
Completed |
NCT02577536 -
PregSource: Crowdsourcing to Understand Pregnancy
|
||
Not yet recruiting |
NCT06336434 -
CREATE - Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT05412238 -
Formulation and Evaluation of the Efficacy of Macro- and Micronutrient Sachets on Pregnant Mothers and Children Aged 6-60 Months
|
N/A | |
Not yet recruiting |
NCT04786587 -
Alcohol Self-reporting During Pregnancy. AUTOQUEST Study.
|
||
Not yet recruiting |
NCT05028387 -
Telemedicine Medical Abortion Service Using the "No-test" Protocol in Ukraine and Uzbekistan.
|
||
Completed |
NCT02783170 -
Safety and Immunogenicity of Simultaneous Tdap and IIV in Pregnant Women
|
Phase 4 | |
Completed |
NCT02683005 -
Study of Hepatitis C Treatment During Pregnancy
|
Phase 1 | |
Recruiting |
NCT02564250 -
Maternal Metabolism and Pregnancy Outcomes in Obese Pregnant Women
|
N/A | |
Recruiting |
NCT02619188 -
Nutritional Markers in Normal and Hyperemesis Pregnancies
|
N/A | |
Recruiting |
NCT02507180 -
Safely Ruling Out Deep Vein Thrombosis in Pregnancy With the LEFt Clinical Decision Rule and D-Dimer
|
||
Terminated |
NCT02537145 -
PregnanT Moms Measure - Do-It-Yourself Health Monitoring and Simulation of Health in Pregnant Women
|